PAG
ZNTL icon

Private Advisor Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Private Advisor Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.6K Buy
+31,472
New +$81.3K ﹤0.01% 2559

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Private Advisor Group's ZNTL Position: Q1 2026 in Review

Private Advisor Group opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 31,472 shares worth $73.6K. The stake represents ﹤0.01% of the portfolio and ranks #2559 among its holdings.

102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Private Advisor Group held 31,472 shares of Zentalis Pharmaceuticals worth $73.6K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Private Advisor Group position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q1 2026, its #2559 holding.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.